BioMarin Pharmaceutical Story

BioMarin Pharmaceutical Inc -- USA Stock  

USD 85.95  1.85  2.20%

Macroaxis does not monitor all media channels or aggregates social signals for BioMarin Pharmaceutical. But even though we do not provide professional-grade financial sentiment analysis on BioMarin Pharmaceutical, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for BioMarin Pharmaceutical. Check also BioMarin Pharmaceutical Hype Analysis, BioMarin Pharmaceutical Correlation and BioMarin Pharmaceutical Performance
Bona fide gift to Robert Baffi of 2675 shares of BioMarin Pharmaceutical subject to Section 16
Filed transaction by Biomarin Pharmaceutical I officer. Exempt bona fide gift subject to Rule 16b-3

BioMarin Pharmaceutical Inc insider trading alert for gift of common stock by Robert Baffi, EVP Technical Operations, on January 3, 2018. This event was filed by Biomarin Pharmaceutical I with SEC on 2016-03-07. Statement of changes in beneficial ownership - SEC Form 4. Robert Baffi is currently serves as executive vp of technical operations of BioMarin Pharmaceutical

Cash Floor Correlation

Click cells to compare fundamentals   View All Correlations

Story Momentum

This media report from MacroaxisInsider distributed on January 3, 2018 was a factor to the next trading day price decrease.The overall trading delta against the next closing price was 1.91% . The overall trading delta when the story was published against the current closing price is 8.91% .

Similar stores for BioMarin Pharmaceutical

a day ago at 
Todays Hot Stock Under Review BioMarin Pharmaceutical Inc
Stocks PenFull coverage
over three weeks ago at 
Biomarin Pharmaceutical Share Price Declined While Jpmorgan Chase Company Has Cut by 16.50 Million ...
Herald KSFull coverage
over a month ago at 
Healthcare Stock to Buy BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. stock price moved with surging change along with the volume 0.83 million shares in Friday trading session.

Did you try this?

Run Efficient Frontier Now

Efficient Frontier

Plot and analyze your portfolio and positions against risk-return landscape of the market.
Hide  View All  NextLaunch Efficient Frontier

Price to Earning

Price to Earning Comparative Analysis
BioMarin Pharmaceutical is currently under evaluation in price to earning category among related companies. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investor monitor on a daily basis. Holding a low PE stock is less risky because. When a company's profitability fall, it is likely that earnings will also go down..In other words, if you start from a lower position your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.